You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黄医药与创响生物合作开发4款免疫性疾病候选药物
阿思达克 01-11 09:41
和黄医药(HCM.US)公布,与创响生物(Inmagene Biopharmaceuticals)达成战略合作,将共同进一步开发由和黄医药发现的4款用於治疗多种免疫性疾病的候选药物,创响生物将投入资金,双方并合作推进提交候选药物新药临床试验(IND)申请。倘若成功,创响生物将负责继续推进候选药物的全球临床开发。

根据协定条款,和黄医药将授予创响生物4款候选药物用於免疫性疾病治疗的独家选择权。若行使该选择权,创响生物将拥有在全球进一步开发、生产和商业化该候选药物的权利,而和黄医药将保留在中国大陆共同商业化的优先权。

对於每款候选药物,和黄医药有权收取最高可达9,500万美元的开发里程碑费用和最高可达1.35亿美元的商业销售里程碑费用,以及商业化後最高可达双位数的年净销售额分成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account